Top 10 Companies in the Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate Market (2026): Market Leaders Powering Global Innovation

MARKET INSIGHTS

Global Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate market size was valued at USD 3.12 million in 2025. The market is projected to grow from USD 3.25 million in 2026 to USD 4.25 million by 2034, exhibiting a CAGR of 3.9% during the forecast period.

Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate, CAS 116613‑81‑1, is a chiral building block and pharmaceutical intermediate. It is a key synthon in the synthesis of various active pharmaceutical ingredients (APIs), especially for non‑steroidal anti‑inflammatory drugs (NSAIDs) and other therapeutic agents targeting pain and inflammation. Its molecular structure, featuring both a carbamate protecting group and a hydroxypentenyl chain, makes it a versatile precursor in complex organic syntheses.

The market is experiencing steady growth, primarily driven by the consistent demand for innovative pharmaceuticals and the expansion of the fine chemicals industry. The rising prevalence of chronic inflammatory diseases globally is a significant factor propelling the need for advanced drug intermediates. Furthermore, the trend toward custom synthesis and outsourcing by major pharmaceutical companies to specialized chemical manufacturers in regions like Asia‑Pacific is creating new opportunities. Key players such as Zen Chemicals, Chengdu AstaTech, and Nanjing Dernor Pharmaceutical are strengthening their positions through technological advancements and capacity expansions to meet the evolving demands of the market.

Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate Market – View in Detailed Research Report

🔟 1. Zen Chemicals

Headquarters: Shanghai, China
Key Offering: High‑purity (>99%) chiral intermediates for NSAID synthesis

Zen Chemicals has established itself as a leading supplier of chiral building blocks, leveraging advanced asymmetric synthesis technologies and a robust quality assurance framework. Their production facilities are equipped with state‑of‑the‑art continuous flow reactors, enabling scalable and cost‑effective manufacturing of Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate.

Sustainability & Growth Initiatives:

• Investment in green chemistry protocols to reduce solvent usage
• Partnerships with major pharmaceutical firms for joint R&D on low‑toxicity routes
• Expansion of production capacity by 30% to meet rising demand in Asia‑Pacific

9️⃣ 2. Chengdu AstaTech

Headquarters: Chengdu, China
Key Offering: Custom synthesis of chiral intermediates for drug development

Chengdu AstaTech specializes in tailor‑made synthesis services, providing rapid turnaround for complex chiral molecules. Their expertise in chiral chromatography and crystallization ensures consistently high purity levels, essential for pharmaceutical applications.

Sustainability & Growth Initiatives:

• Implementation of renewable energy sources across manufacturing sites
• Development of a proprietary chiral catalyst library to accelerate synthesis
• Strategic collaborations with CROs to secure long‑term supply contracts

8️⃣ 3. Nanjing Dernor Pharmaceutical

Headquarters: Nanjing, China
Key Offering: API‑grade chiral intermediates for global pharmaceutical markets

Nanjing Dernor has a strong focus on delivering API‑grade intermediates with stringent quality controls. Their facilities comply with international GMP standards, making them a trusted partner for multinational drug manufacturers.

Sustainability & Growth Initiatives:

• Adoption of zero‑waste production processes
• Expansion of R&D capabilities in asymmetric synthesis
• Establishment of a global distribution network covering North America, Europe, and Asia‑Pacific

7️⃣ 4. Hangzhou Chempro

Headquarters: Hangzhou, China
Key Offering: Bulk chiral intermediates for fine chemical manufacturing

Hangzhou Chempro provides high‑volume production of chiral intermediates, focusing on cost‑efficiency and scalability. Their automated synthesis lines enable rapid scale‑up while maintaining product consistency.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recovery systems
• Investment in digital process monitoring for real‑time quality control
• Strategic partnership with European fine chemical firms

6️⃣ 5. Chengdu Fucos Pharmaceutical

Headquarters: Chengdu, China
Key Offering: Advanced chiral intermediates for specialty drug development

Chengdu Fucos focuses on high‑purity intermediates for specialty pharmaceuticals, including anticancer and antiviral agents. Their research team is actively developing novel synthetic routes that reduce reliance on traditional Boc protection.

Sustainability & Growth Initiatives:

• Use of bio‑based solvents in synthesis processes
• Collaboration with academic institutions for green chemistry research
• Expansion of manufacturing capacity in response to emerging therapeutic demands

5️⃣ 6. Beijing BioChem

Headquarters: Beijing, China
Key Offering: High‑purity chiral intermediates for API production

Beijing BioChem combines traditional synthesis expertise with modern automation to deliver consistent, high‑quality intermediates. Their focus on process optimization reduces production costs and enhances scalability.

Sustainability & Growth Initiatives:

• Adoption of renewable energy for manufacturing facilities
• Implementation of AI‑driven process control systems
• Strategic alliances with global CROs for contract manufacturing

4️⃣ 7. Shanghai FineChem

Headquarters: Shanghai, China
Key Offering: Specialty chiral intermediates for fine chemical synthesis

Shanghai FineChem specializes in the production of specialty chiral intermediates, offering a broad portfolio that includes Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate. Their quality systems align with ISO 9001 and ISO 14001 standards.

Sustainability & Growth Initiatives:

• Integration of water‑recycling systems in production
• Investment in continuous flow chemistry to improve yield
• Expansion of product lines to include emerging therapeutic agents

3️⃣ 8. Guangzhou ChemSynth

Headquarters: Guangzhou, China
Key Offering: Custom synthesis of chiral intermediates for pharmaceutical companies

Guangzhou ChemSynth provides bespoke synthesis solutions, leveraging a modular manufacturing approach that allows rapid adaptation to client specifications. Their focus on rapid prototyping supports early‑stage research and development.

Sustainability & Growth Initiatives:

• Use of green solvents and recyclable reagents
• Collaboration with industry consortia to develop sustainable synthesis routes
• Expansion of global logistics to improve supply chain resilience

2️⃣ 9. Shenzhen AdvancedChem

Headquarters: Shenzhen, China
Key Offering: High‑throughput synthesis of chiral intermediates for drug discovery

Shenzhen AdvancedChem specializes in high‑throughput synthesis platforms, enabling rapid library generation for drug discovery programs. Their advanced analytical capabilities ensure stringent purity and stereochemical control.

Sustainability & Growth Initiatives:

• Implementation of modular, scalable reactors for flexible production
• Investment in waste‑to‑energy conversion technologies
• Partnerships with global research institutions for joint R&D

1️⃣ 10. Wuhan PharmaTech

Headquarters: Wuhan, China
Key Offering: API‑grade chiral intermediates with a focus on cost‑effective manufacturing

Wuhan PharmaTech offers cost‑effective production of API‑grade chiral intermediates, leveraging process intensification and continuous flow technologies to reduce manufacturing footprint.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources across production lines
• Development of proprietary catalysts to improve reaction efficiency
• Expansion of distribution networks in emerging markets

Download FREE Sample Report: Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate Market – View in Detailed Research Report

Get Full Report Here: Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate Market – View in Detailed Research Report

Outlook: The Future of Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate Market

The Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate market is poised for steady expansion, driven by the growing need for enantiomerically pure intermediates in pharmaceutical development. Key factors shaping the outlook include:

• Continued rise in chronic inflammatory disease prevalence, fueling demand for NSAIDs and related APIs.
• Increasing adoption of continuous flow chemistry and automation, improving scalability and reducing costs.
• Strategic collaborations between intermediate suppliers and global pharmaceutical manufacturers, ensuring long‑term supply security.
• Regulatory emphasis on high‑purity intermediates, driving quality upgrades across the supply chain.

Future Trends Shaping the Market

• Development of alternative synthetic routes that bypass Boc protection, potentially reducing cost and environmental impact.
• Expansion into emerging therapeutic areas such as antiviral and anticancer agents, where the chiral configuration of Tert‑butyl (S)-(1‑hydroxypent‑4‑en‑2‑yl)carbamate offers unique advantages.
• Integration of digital technologies for real‑time process monitoring and predictive maintenance, enhancing manufacturing reliability.
• Growth of contract research and manufacturing (CRAM) services, providing specialized expertise to pharmaceutical companies worldwide.